TD Cowen acted as sole book running manager for the offering.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Jasper Therapeutics announces common stock offering, no amount given
- Jasper Therapeutics price target lowered to $25 from $29 at UBS
- Hold Rating on Jasper Therapeutics Amid Uncertainty in BEACON Study and Drug Development Timeline
- Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays and Competitive Pressures
- Jasper Therapeutics: Promising Clinical Data and Strategic Focus Drive Buy Rating